The development of cancer is fundamentally rooted in alterations to the genome, encompassing a range of genetic mutations, epigenetic modifications, and chromosomal instability.  These genomic aberrations can disrupt crucial cellular processes, including cell cycle regulation, DNA repair, and apoptosis, ultimately leading to uncontrolled cell proliferation and tumorigenesis. Advances in next-generation sequencing (NGS) technologies have revolutionized our understanding of this genetic landscape, allowing for the identification of specific driver mutations and other genomic alterations within individual tumors. This has paved the way for personalized medicine approaches in oncology.  Practical applications include the selection of targeted therapies matched to specific oncogenic drivers, exemplified by the use of EGFR inhibitors in lung cancers with EGFR mutations. Furthermore, genomic profiling aids in predicting treatment response and identifying patients at high risk of recurrence, enabling more precise treatment strategies and improved patient stratification.  This personalized approach extends to immunotherapy, where genomic analyses can predict the likelihood of responding to checkpoint inhibitors based on tumor mutational burden or microsatellite instability status.  While challenges remain in terms of data analysis and cost-effectiveness, the integration of genomic information into cancer care is rapidly transforming the field, offering the potential for more effective and less toxic treatments tailored to the unique genetic profile of each patient.